The MHRA is consulting with UK stakeholders to gather feedback and comments on a new international guideline for the appropriate inclusion and/or retention of pregnant and/or breast-feeding individuals in clinical trials of medicines.
Similar Posts
UK clinical trial approval times twice as fast with AI and reforms
Patients receive earlier access to life-saving treatments as UK trial approval times cut in half from 91 to just 41 days.
Side effects from drug interactions to be predicted by AI before reaching patients
The MHRA leads three new government-backed projects using AI-driven approaches to make medicines safer and bring treatments to patients more quickly.
Man jailed for ten years for convictions including selling prescription-only medicines worth more than £3.7 million
A man who unlawfully supplied Class B and Class C controlled drugs and a range of unauthorised medicines has been sentenced at Stoke-on-Trent Crown Court following an investigation by the MHRA’s Criminal Enforcement Unit.
Keep the warmth, lose the risk: MHRA and National Fire Chiefs Council issue winter emollient safety warning
As colder weather arrives, the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Fire Chiefs Council (NFCC) are urging the public to be aware of fire risks linked to emollient skin creams.
Decision: Advertising Investigations: January 2026
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Isotretinoin – changes to prescribing guidance and additional risk minimisation measures
The Commission on Human Medicines (CHM) has endorsed changes to the risk minimisation measures for isotretinoin, following a review of the impact of the measures implemented in 2023. We ask healthcare professionals to review these new measures and supporting materials and integrate them into their clinical practice.